Nanovibronix (NASDAQ:FEED) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Nanovibronix (NASDAQ:FEEDFree Report) from a sell rating to a strong sell rating in a research report sent to investors on Monday.

Separately, Weiss Ratings initiated coverage on Nanovibronix in a research report on Tuesday, January 27th. They issued a “sell (e+)” rating for the company. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nanovibronix presently has a consensus rating of “Sell”.

Get Our Latest Research Report on FEED

Nanovibronix Stock Performance

Shares of FEED stock opened at $1.35 on Monday. The company has a market capitalization of $1.47 million, a PE ratio of -0.03 and a beta of 2.09. Nanovibronix has a one year low of $0.99 and a one year high of $62.39. The business has a fifty day moving average price of $2.00.

Nanovibronix (NASDAQ:FEEDGet Free Report) last issued its earnings results on Wednesday, April 15th. The company reported ($20.00) EPS for the quarter. The firm had revenue of $0.31 million during the quarter. Nanovibronix had a negative return on equity of 47.82% and a negative net margin of 712.30%.

Nanovibronix Company Profile

(Get Free Report)

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.

Featured Stories

Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.